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ABSTRACT 
Histomoniasis, commonly known as blackhead disease, has increased in prevalence due 
to the regulatory ban of prophylactics and therapeutics within the past 30 years.  The objective of 
this thesis was to evaluate the efficacy of selected dietary chemoprophylaxis candidates as well 
as an in vitro live-attenuated vaccine candidate Histomonas meleagridis for prevention of 
histomoniasis. Chapter one addresses deoxycholic acid and a biliogenic diet intended to 
endogenously increase production of this secondary bile acid. Deoxycholic acid was effective in 
vitro but failed to prevent histomoniasis when evaluated during the in vivo experimental disease 
trial with turkeys. The biliogenic diet did not reduce disease prevalence. Chapter two addresses 
dietary inclusion of 0.2% boric acid to prevent disease. The selected concentration of boric acid 
was unsuccessful in disease prevention. Chapter three addresses the experiments conducted to 
evaluate select ages, doses, and routes of a candidate live-attenuated vaccine. The live-attenuated 
vaccine candidate has exhibited slight reduction in histomoniasis severity when administered 
intracloacally on d14. Although the practicality of this current experimental vaccine 
administration approach may be limited, further research must be conducted in order to further 
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Histomoniasis (also known as blackhead, infectious enterohepatitis, and histomonosis) is 
an important disease of poultry, especially turkeys, which can be vectored by the Heterakis 
gallinarum cecal worm, earthworm, or other birds such as chickens (Tyzzer and Fabyan, 1922; 
van der Heijden et al., 2005; Hess et al., 2015). Caused by the protozoan parasite Histomonas 
meleagridis, initial signs of disease often consist of declined feed consumption, drooping wings, 
head-tucking, or inactivity (Duffy et al., 2005). Transmission occurs via cloacal drinking which 
can rapidly transfer pathogens through the cloaca to the bursa of Fabricius or ceca via rhythmic 
contractions that draw the material inside the vent (Hu et al., 2004; McDougald and Fuller, 
2005). 
Lack of research within the past 30 years, in addition to the ban of therapeutic and 
prophylactic compounds, has resulted in lack of methods for controlling this disease (van der 
Heijden et al., 2005; Hess et al., 2006). There is a need for evaluation of anti-protozoal 
compounds (chemical and non-chemical) or vaccines for the control of histomoniasis and other 
protozoal diseases (such as coccidiosis, caused by Eimeria spp.). Unfortunately, an alternative to 
the previously used drugs has not yet been established, because in vitro and in vivo studies 
continue to yield variable results against histomoniasis (Thøfner et al., 2012). 
Previous immunological research results have been largely unsuccessful, creating doubts 
for successful vaccine development (Hu and McDougald, 2004). However, in 1963, Joyner 
treated H. meleagridis-infected turkeys with dimetridazole and reported recovered turkeys to be 
resistant to subsequent infection, suggesting development of protective immunity. Turkeys 
recovered from H. meleagridis infection and subsequently challenged to evaluate immunity have 
exhibited resistance to characteristic disease symptoms and lesions even when harboring H. 
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meleagridis within the cecae (Cuckler, 1970). Intracloacal administration of in vitro-attenuated 
H. meleagridis has resulted in reduced liver and cecal lesions within chickens and turkeys in 
previous studies (Hess et al., 2008; Liebhart et al., 2013). In vitro passaging and subsequent 
serial passaging of H. meleagridis within turkeys and chickens resulted in no reversion to 
virulence (Sulejmanovic et al., 2013). Furthermore, cross-protection against heterologous 
virulent isolates was demonstrated by vaccinating with an attenuated clonal strain of H. 
meleagridis developed through prolonged in vitro culture methods (Sulejmanovic et al., 2016). 
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II. LITERATURE REVIEW 
 
The ban of nitroimidazoles, nitrofurans, and arsenical compounds for prophylaxis and 
treatment in the last 30 years has led to the lack of preventative options for histomoniasis, a 
disease primarily affecting turkeys. The following summarizes the disease, chemoprophylaxis 
compounds focused on the mitigation of this problem, and previous immunization attempts. In 
addition, an overview of the bile acid pathway and dietary inclusions to increase endogenous 
production of deoxycholic acid will be summarized, because this compound was selected as an 
anti-histomonal candidate.  
HISTOMONIASIS: A GENERAL OVERVIEW 
Histomoniasis (also known as blackhead, infectious enterohepatitis, and histomonosis) is 
a protozoal disease affecting the gastrointestinal tract of turkeys, chickens, and other 
gallinaceous birds (van der Heijden et al., 2005; Hess et al., 2015). High mortality occurs in 
turkeys, whereas less severe damage occurs in chickens and other galliformes (Callait et al., 
2002). Considered critically and economically impactful to both turkeys and chickens, 
histomoniasis is a serious and ongoing concern facing the poultry industry (Duffy et al., 2005; 
Lotfi et al., 2014). 
Histomonas meleagridis is included in the phylum Sarcomastigophora with further 
taxonomic classification in the order Tritrichomonadida and family Dientamoebidae (Cepicka et 
al., 2010; Hess and McDougald, 2013). The etiological agent of histomoniasis, H. meleagridis 
penetrates the cecal epithelial lining, replicates, enters the bloodstream and parasitizes the liver 
(Clarkson, 1963; Hess and McDougald, 2013). Hepatic liver lesions and tissue necrosis are 
common within diagnosed birds, while individual histomonads can be observed within infected 
tissues using electron microscopy. Cultivation of H. meleagridis has occurred from liver lesions 
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(Bayon and Bishop, 1937; Bishop, 1938). Overt signs of histomoniasis are often apparent at 
eleven days post-infection while thickening and reddening of the mucosal layer of the ceca 
begins within three days of infection (Hess and McDougald, 2013). Although commonly referred 
to as blackhead within industry and laymen’s terms, the clinical sign of cyanosis of the head are 
neither pathognomonic nor distinctive to histomoniasis because other diseases produce a similar 
appearance (Sentíes-Cué et al., 2009; Hess and McDougald, 2013). Initial symptoms can include 
declining feed consumption, drooping wings, unkempt feathers, or inactivity (Duffy et al., 2005). 
Necrotic typhlitis (necrosis and inflammation of the cecae), hepatitis, sulfuric excreta, and high 
mortality are characteristic pathological signs (Callait et al., 2002; Hess et al., 2015). 
Severe mortality results in turkeys with an estimated annual loss of over two million 
dollars and mortality approaching 80-100% in an affected flock (Callait et al., 2002; McDougald, 
2005; Hess and McDougald, 2013). Although mortality is not as significant in chickens, 
economic losses are estimated to exceed those of turkeys due to greater frequency of disease and 
the larger number of flock infections within chickens (Callait et al., 2002). Chicken mortality can 
be 10-20% with a high morbidity but an outbreak frequently is unnoticed or results in increased 
condemnations at the broiler processing plant (McDougald, 2005). Mortality is most commonly 
observed between nine and twelve days post-infection (Hess and McDougald, 2013). 
Beginning in the 1960s, research on this organism waned because the introduction of 
nitroimidazoles, nitrofurans, and arsenical compounds for prophylactic treatment against 
outbreaks was made available and successfully controlled the disease (van der Heijden et al., 
2005; Hess et al., 2006). Concerns over heavy metal retention within meat products from treated 
poultry resulted in the 2015 regulatory removal of Nitarsone (Histostat), the last remaining FDA-
approved drug for treatment of histomoniasis (Regmi et al., 2016). Without viable substitute 
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treatment options and no new alternatives, producers are now suffering from the losses of broiler 
breeders, layer pullets, and turkeys (Hu and McDougald, 2004). 
Pathogenesis 
 The trichomonad parasite H. meleagridis is capable of existing as either an amoeboid or 
single-flagellated form, and can be transmitted directly from bird to bird or through intermediate 
hosts and vectors (Lotfi et al., 2014). Lacking mitochondria, H. meleagridis possesses an 
organelle called the hydrogenosome responsible for anaerobic energy metabolism (McDougald, 
2005; Hauck et al., 2010; Hess and McDougald, 2013). These protozoa have a typical median 
diameter of approximately 10µm, ranging from 6-20µm, and usually exist in amoeboid form but 
may also exist with a single flagellum (Hess and McDougald, 2013). Recent research has 
suggested the possible formation of cyst-like stages in vitro observed with detailed light and 
transmission microscopy (Zaragatzki et al., 2010a; b). Isolates can be cultured from infected 
birds and grown in vitro, with long-term cultivation shown to result in a different phenotype, 
increased growth, and higher tenacity in adverse conditions (Gruber et al., 2017).  A larger, 
nonpathogenic species, Histomonas wenreichi or Parahistomonas wenrichi, was later discovered 
and has a typical size of 20-30µm and 3-4 flagella (McDougald, 2005).  
Although the life cycle of H. meleagridis is not fully understood, it has been 
characterized as an extracellular parasite that reproduces through binary fission (Tyzzer, 1920; 
Cuckler, 1970). Direct oral ingestion of histomonads has not recreated the disease reliably in 
previous research, presumably due to the adverse acidity and mechanical action within the crop 
and ventriculus (gizzard) of the bird (Hu et al., 2004). Histomonads are delicate in nature and 
cannot withstand living long periods of time in the environment unless protected by a vector 
such as the heterakid worm or earthworm (McDougald and Fuller, 2005). The cecal worm 
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Heterakis gallinarum has been identified as an important vector and reservoir for disease 
transmission; H. meleagridis have been observed within the intestinal wall, larvae, and eggs of 
this cecal nematode (Hess et al., 2015). Heterakis gallinarum appears to provide a protective 
barrier to transport the infective material through the gastrointestinal tract of poultry, leading to 
establishment of disease (Tyzzer and Fabyan, 1922; Hu et al., 2004). Ingestion of embryonated 
heterakid eggs or the adult cecal worms by poultry can result in H. meleagridis infection (Hu et 
al., 2004). Regular earthworms can also ingest histomonad-infected cecal worm eggs, and 
thereby act as a transport host for the infected heterakid eggs (Lund et al., 1966; Hu et al., 2004).  
Other protozoa and nematodes have similar transmission methods; the Enterobius vermicularis 
nematode can serve as a vector of Dientamoeba fragilis, an intestinal trichomonad parasite 
primarily of humans, facilitating transmission of disease (Clark et al., 2014).  
Rapid transmission by direct contact between infected birds or fecal droppings can occur 
without an intermediate host or vector if transmission occurs before the fragile histomonads die 
(Sentíes-Cué et al., 2009). Once a turkey is infected, disease can quickly transmit to others in the 
flock within two or three days, causing an outbreak (Hess and McDougald, 2013). Interestingly, 
this method of transmission occurs primarily through the cloacal drinking phenomenon rather 
than standard fecal-oral or respiratory-respiratory transmission. This cloacal drop or cloacal 
drinking can rapidly transfer disease through the cloaca to the bursa of Fabricius or ceca via 
rhythmic contractions that draw the infectious material inside the vent (Hu et al., 2004; 
McDougald and Fuller, 2005). Infection has been produced with the cloacal injection of infected 
tissue (liver or cecae) as well as with a suspension of histomonad culture (Berks and Neal, 1952). 
Recently, oral administration of a clonal in vitro-cultured H. meleagridis to 1-day-old turkeys 
followed by 5h feed restriction resulted in histomoniasis mortalities, suggesting a potential oral 
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infection route if large amounts of contaminated excreta or litter are ingested (Liebhart and Hess, 
2009). 
To further complicate the understanding of this disease, commensal bacterial flora have 
been found to be important in disease development (McDougald, 2005). Unfortunately, the cecal 
environment wherein H. meleagridis resides is constantly in a state of flux, making permanent 
microflora adjustments as a method of controlling this disease difficult (Callait et al., 2002). The 
nitroimidazole-class drug dimetridazole was previously an effective treatment for histomoniasis; 
however, the ban of effective prophylactic and therapeutic compounds such as this have resulted 
in measures focused upon prevention rather than treatment of the disease (Joyner, 1963; Hess 
and McDougald, 2013; Liebhart et al., 2013). In 2015, the arsenic-based drug nitarsone 
(Histostat), the last remaining FDA-approved drug for prevention of histomoniasis, was 
withdrawn from the market due to concerns about inorganic arsenic levels in treated poultry 
(Regmi et al., 2016). Overall effectiveness is limited, but outbreaks can be reduced with careful 
animal management practices (Liebhart et al., 2017). The disease is generally more prevalent 
when birds are housed in environments favoring the coexistence of the cecal nematode H. 
gallinarum, the primary local reservoir for infection (Hess and McDougald, 2013). Chickens 
often serve as reservoirs for the cecal worm and pose as sources for potential infection; therefore, 
separate rearing should occur between poultry species to prevent resulting cross-transmission 
outbreaks (Bayon and Bishop, 1937; McDougald, 2005; Hess and McDougald, 2013). 
SELECTED CHEMOPROPHYLAXIS COMPOUNDS 
Anti-histomonal drugs, plant-derived compounds, and vaccination attempts have been 
reviewed by Liebhart et al. (2017). Recent research has focused primarily in the areas of 
antiprotozoal compounds, antibiotics, vaccines, and plant products with chemical activity (Hess 
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et al., 2015). Treatment is challenging because protozoa are eukaryotic organisms; selective 
toxicity is crucial so that the chemoprophylaxis compound is harmful to the parasite without 
causing irreversible damage to the host. With the increasing world population, finding methods 
to prevent and treat diseases such as histomoniasis are crucial for the overall well-being of 
animal husbandry and food production. Additionally, the implications of discovering anti-
protozoal compounds that could have beneficial applications towards other protozoal diseases 
are remarkable and warrant further research for the potential benefit of animals and humans 
alike. However, identifying alternatives to the previously used drugs has not yet been 
established, because in vitro and in vivo studies continue to yield variable results against 
histomoniasis (Thøfner et al., 2012). The close relationship of H. meleagridis to other amoebae 
and flagellates suggests any anti-protozoal compounds effective against H. meleagridis may also 
have activity against related protozoal species (Hu and McDougald, 2004). If a compound were 
discovered, this could revolutionize the potential for efficacious treatment of other protozoa such 
as Tetratrichomonas and Entamoeba (Hess et al., 2006; Nakada-Tsukui and Nozaki, 2016). 
Deoxycholic acid 
 Deoxycholic acid (DCA), a naturally occurring secondary bile acid, has been shown to 
reduce severity of Eimeria maxima and Clostridium perfringens infections in poultry when 
administered at a concentration of 1.5 g/kg in the diet by reducing intestinal villi damage (Wang 
et al., 2018). A study in mice resulted in anaerobic bacteria-derived DCA protection against 
colitis induced by Campylobacter jejuni (Sun et al., 2018). Considering these results, the 
hypothesis that DCA might confer anti-histomonal properties is investigated in the first chapter. 
Overview of bile acids. Within the small intestine, the homeostatic control of cholesterol 
and the absorption of dietary fatty acids are reliant upon biliary lipid secretions that include bile 
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acids (LeBlanc et al., 1998). Cholic acid (CA) and chenodeoxycholic acid (CDCA) are the 
primary bile acids (Stamp and Jenkins, 2008). Cholesterol is an important precursor for bile 
acids, while bilirubin, heavy metals (such as copper and iron), and urine insoluble lipophilic 
steroids are constituent components of bile acids (Stamp and Jenkins, 2008; Boyer, 2013). Liver 
hepatocytes synthesize bile acids, which are water-soluble amphipathic molecules resulting from 
cholesterol catabolism (Stamp and Jenkins, 2008; Winston and Theriot, 2016). According to 
Lefebvre et al., (2009), the “classical pathway” for bile acid synthesis uses cholesterol 7α-
hydroxylase (CYP7A1) and contributes to approximately 75% of bile acid synthesis within the 
liver. However, the alternative, “acidic pathway” initiated by sterol 27-hydroxylase (CYP27A1) 
is responsible for the remaining 25% of the bile acid synthesis (Lefebvre et al., 2009). The 
gallbladder functions as the storage organ for bile acids and approximately 5% of these stored 
bile acids will be fecally excreted (Stamp and Jenkins, 2008). Additionally, cholecystokinin 
released from the duodenum following a meal initiates gallbladder contraction, stimulating the 
flow of bile (Ridlon et al., 2006; Lefebvre et al., 2009). A vast canalicular network comprised 
from apical membranes of hepatocytes and bile duct cholangiocytes results in the bile-secretory 
unit (Boyer, 2013).  
Bile acids contribute to multiple important physiological functions and pathways 
including: 1) the excretory pathway to clear harmful exogenous substrates that are not readily 
processed by the kidney; 2) bile salts, which are organic solute components in bile acid that 
emulsify and facilitate the digestion of fats; 3) the cholesterol elimination pathway; 4) the 
excretion of IgA, inflammatory cytokines, and innate immune system stimulation; 5) 
enterohepatic circulation component; and 6) excretion mechanisms for intestinal growth 
hormones (Boyer, 2013). Bile acids are cytotoxic at high concentrations, and can lead to 
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carcinogenesis within some visceral organs and tissues (Stamp and Jenkins, 2008; Lefebvre et 
al., 2009). The hydrophobicity of the bile acids is potentially linked to the toxicity of the 
molecules, and the increased number of hydroxyl groups is inversely related to toxicity (Stamp 
and Jenkins, 2008).  However, bile acids function as biological detergents, aiding in the 
production of antimicrobial peptides and contributing to host defense against pathogens 
(Winston and Theriot, 2016).  
Bile acid conjugation. Bile acids are commonly referred to as bile salts, although this 
may be a more appropriate term when the conjugated bile acids are linked with sodium or 
potassium salts. Largely impermeable to the intestinal enterocytes, conjugated bile acids are 
usually restricted to the gastrointestinal lumen due to increased aqueous solubility, ensuring the 
likelihood of distribution with digesta (Stamp and Jenkins, 2008). The increased levels of bile 
acids within the lumen initiate micelle formation that contributes to the emulsification and 
absorption of lipids (Lefebvre et al., 2009). The micelle aids in the diffusion of lipids as they 
travel the length of the gastrointestinal tract, while also contributing to the reabsorption of bile 
acids within the distal ileum (Stamp and Jenkins, 2008). 
Glycine-conjugated bile acids are the most abundant and represent greater than 70% of 
bile (Stamp and Jenkins, 2008). The conjugated form is denied entry to epithelial cells thereby 
protecting the organs and restricting its presence to within the gastrointestinal lumen (Stamp and 
Jenkins, 2008). Taurine-conjugated bile acids are present in lower abundance but contribute to 
approximately 20% of bile (Stamp and Jenkins, 2008). Conjugation of CA or CDCA to either 
glycine or taurine is common; conjugated bile acids are excreted into the lumen of the 
gastrointestinal tract to facilitate metabolism of fats and fat-soluble vitamins (Van Eldere et al., 
1996). Passive reabsorption is prevented due to the stronger acidic nature produced from 
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conjugation as the bile acids travel through the biliary ducts (Boyer, 2013). The taurine 
conjugated bile acids have detergent properties and are soluble within the normal acidic stomach 
environment (Stamp and Jenkins, 2008). This solubility contributes to its potential entry into the 
gastrointestinal epithelial cells. Not surprisingly, taurine supplementation has be shown to 
negatively impact intestinal mucosal development through its role in toxic bile acid generation 
within broiler chickens (Huang et al., 2014).  
Free bile acids. Free bile acids are produced via bacterial enzymes that deconjugate 
primary bile acids within the ileum and the large intestine (Cole and Fuller, 1984). Moreover, 
bacterial hydroxysteroid dehydrogenases further convert free bile acids into secondary bile acids 
via a 7α-dehydroxylase reaction. Other enzymatic reactions may occur through 3α- and 7α- 
hydroxysteroid dehydrogenases as well, but the 7α-dehydroxylation is unique to a few anaerobic 
species (Winston and Theriot, 2016). Deconjugation reactions within the small intestine and 
dihydroxylation reactions within the large intestine are the two predominant methods by which 
secondary bile acids are produced (Winston and Theriot, 2016). Moreover, reconjugation with 
glycine or taurine can occur, renewing levels of primary and secondary bile acids during 
enterohepatic recirculation. 
Within the lower gastrointestinal tract, the secondary bile acids formed include DCA and 
lithocholic acids (LCA) that are produced from CA and CDCA, respectively (Van Eldere et al., 
1996; Ridlon et al., 2006). Many other bile acids may also be formed via bacterial enzymatic 
reactions and conjugations, but the above mentioned are the more common bile acids (Stamp and 
Jenkins, 2008). Increased secondary bile acids have been associated with the etiologies of 
cholesterol gallstone disease and colon carcinogenesis (Winston and Theriot, 2016). Considering 
this impact against eukaryotic cells, DCA was considered to potentially exhibit toxicity to H. 
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meleagridis. High plasma cholesterol levels, particularly low-density lipoprotein cholesterols, are 
associated with increased risks of cardiovascular disease (Yang et al., 2012). An inverse 
relationship appears to exist for CDCA and DCA, meaning that the increasing DCA 
concentrations are linked with decreasing CDCA (Ridlon et al., 2006). This is understandable in 
that DCA is formed from the catabolism of CDCA.  
Enterohepatic recirculation. The formation of secondary bile acids is important to the 
enterohepatic circulation that can occur as often as ten times a day. Both primary (CA and 
CDCA) and secondary (LCA and DCA) bile acids are circulated and reabsorbed through the 
enterohepatic system (Stamp and Jenkins, 2008). This reabsorption process occurs when DCA 
and LCA enter the portal veins and circulate to the liver to join the newly synthesized CA and 
CDCA. Reconjugation to glycine or taurine occurs and these renewed, conjugated bile acids are 
stored in the gallbladder.  The rate-limiting CYP7A1 is suppressed when bile acids are returned 
to the liver via the enterohepatic circulation, thereby inhibiting additional bile acid synthesis 
(Stamp and Jenkins, 2008). The actual regulation of synthesis, metabolism, and transportation of 
bile acids via the enterohepatic system was determined to be self-regulated by the bile acids 
through activation of the Farnesoid X receptor (FXR) (Lefebvre et al., 2009). The FXR is 
expressed within the liver, gastrointestinal tract, kidneys, and adrenal glands. The recirculated 
bile acids bind to the FXR in the liver, resulting in negative feedback and downregulation of 
transcription factors for bile acid synthesis (Stamp and Jenkins, 2008).  
If DCA were capable of conferring anti-histomonal properties in vivo, use as a 
commercial feed additive might be more accepted since DCA is naturally occurring and is 
regenerated during enterohepatic recirculation. Moreover, certain diets have been shown to 
increase bile acid output that indicates the endogenous processes can be altered by dietary 
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composition. If DCA effectively mitigates histomoniasis, an alternative to DCA inclusion in diet 
would be to pursue formulation of a bile-enhancing “biliogenic” diet. This different approach 
might be more economical than directly supplementing DCA into the feed. The literature 
considered for formulation of this biliogenic diet is reviewed below.  
High protein dietary impacts. Within chickens, the atherogenic impact (formation of 
fatty plaques in the arteries) of dietary cholesterols and fats was shown to decline with the 
introduction of higher protein diets (Nishida et al., 1958; Kummerow et al., 1960). Diets high in 
fat are generally associated with the elevated cholesterol levels that are a precursor to bile acids 
(Kokatnur et al., 1958b). An inverse linear relationship between protein intake and levels of 
serum cholesterol was caused in experiments with high protein diets (Kokatnur et al., 1958b). 
Interestingly, in a study conducted by Kokatnur et al. (1958b), hypercholesteremic birds that 
were provided adequate or high protein diets showed a rapid decrease in serum cholesterol. 
Moreover, serum cholesterol values only reached normal levels within hypercholesteremic birds 
when supplemented with high dietary protein. These observations suggest that increased dietary 
protein intake might be a more efficient means of reducing overall cholesterol levels in the serum 
than simply eliminating or decreasing fat consumption (Kokatnur et al., 1958b).  
Furthermore, dietary methionine deficiencies were found to increase serum cholesterol 
(by nearly two-fold as compared to a low protein choline deficient diet), β-lipoprotein levels, and 
total lipids within the sera of chicks (Kokatnur et al., 1958a; Nishida et al., 1958). These results 
suggest the artherogenic effects of imbalanced cholesterol, lipid, and methionine when combined 
with low protein diets (Nishida et al., 1958). Taken together, the apparent connection between 
dietary protein and artherogenic effects suggest the importance of nutritional management of 
dietary proteins rather than dietary fats.  
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The additional role of energy to protein ratio (E/P ratio) was considered by Kokatnur et 
al., (1958a). The E/P ratio was calculated by the following equation: 
	 	
	 	 	100	 .
	 	
 
Low E/P ratios were associated with significantly decreased serum cholesterol levels, presenting 
an additional factor to consider when determining dietary effects (Kokatnur et al., 1958a). 
Egg-enriched diets. Yang et al. (2012), conducted a study with various egg-enriched 
diets to evaluate influences upon cholesterol metabolism, among other factors, in rats. Of 
interest, a diet consisting of 31.25% vacuum freeze-dried egg yolk powder diet (21.78% crude 
protein) and a diet consisting of 55.56% vacuum freeze-dried whole egg powder (36.09% crude 
protein) were included in the study. These diets were compared to control groups provided either 
a standard diet or a 0.75% cholesterol diet. Total bile acid output was higher in all groups as 
compared to the controls and was particularly significant for the whole egg powder diet. Liver 
cholesterol levels within both egg-enriched diets were higher than the control, although the 
0.75% cholesterol diet exhibited the highest level (Yang et al., 2012). However, this indicates the 
influence upon hepatic cholesterol levels within egg-enriched diets.  
CYP7A1, the rate-limiting enzyme for bile acid synthesis from cholesterol, had increased 
mRNA expression within the egg-yolk and whole-egg powder enriched diets as compared to 
both the cholesterol and control diets (Yang et al., 2012). This increased mRNA expression 
indicates that the egg-enriched diets upregulated the CYP7A1 activity, thereby promoting bile 
acid synthesis. Moreover, this increased function may have contributed to the elevated output of 
bile acids within the excreta (Yang et al., 2012). Taken together, the data from this study suggest 
that egg-enriched diets are consistent with the lowering of cholesterol absorption as well as the 
increased excretion of bile acids due to increased rate of synthesis.  
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Lecithin-enriched diets. Lecithin-enriched diets have been shown to increase biliary 
excretions in both rats and chickens (Lindsay et al., 1969; LeBlanc et al., 1998). In 1969, 
Lindsay et al. reported an 81% increase in bile acid excretion based upon fecal matter, and a 
105% increase based upon bird body weight when chicks were fed a 2.5% lecithin diet. A 0.5% 
β-sitosterol diet was also found to increase bile excretions, but to a lesser extent than the lecithin 
diet. Synergistic effects resulted from the combination of the 2.5% lecithin and 0.5% β-sitosterol 
diets, producing higher bile acid excretion than either diet singly (Lindsay et al., 1969)
 LeBlanc et al. (1998) fed rats a 20% lecithin diet that resulted in a 25% increase in bile 
flow and 61% increase in biliary bile acid output. Interestingly, the lecithin diet also contributed 
to a proportional change among the bile acid composition, with DCA significantly increasing 
(LeBlanc et al., 1998). This changed profile could explain why the cholesterol output was also 
increased.  
Considering these factors, Data Chapter 1 evaluates different concentrations of DCA 
inclusion within a basal diet as well as a diet formulated with the intention of endogenously 
increasing bile acid synthesis. The above data contributed to our hypothesis that DCA might be 
effective as a chemoprophylaxis chemical against histomoniasis. However, the complicated 
nature of histomoniasis serves to further emphasize the importance of pairing in vivo studies with 
in vitro experiments to confirm that any chemoprophylaxis activity is conferred within an 
animal. 
Boric acid  
Although boron is an essential element to humans, animals, and plants, the NRC (1994) 
has no recommended level of boron for daily intake in poultry (Eren et al., 2012). Not naturally 
occurring in elemental form, boron is always bound chemically with oxygen to form borates 
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(Moore et al., 1997). Boric acid, a boron compound, is used as a litter treatment for the 
prevention of darkling beetles within the poultry industry, raising concerns that poultry might be 
harmed by the ingestion of the boric acid litter treatment (Sander et al., 1991; Dufour et al., 
1992). Previously, boric acid was shown to be non-toxic when administered orally to 1-day-old 
chicks at a dose of less than 2g/kg body weight, but levels greater than 3.89 g/kg body weight 
resulted in high toxicity (Sander et al., 1991). The acute oral mean lethal dose of boric acid in 1-
day-old chicks was later determined to be 2.95 ± 0.35 g/kg of body weight, resulting in its 
classification as a slightly toxic chemical (Sander et al., 1991). Toxic levels of boric acid can 
result in decreased body weight, increased feed conversion, and abnormal feather growth 
(Dufour et al., 1992). However, in 1992, Dufour et al. demonstrated that litter treatment with 
boric acid at a rate of 0.4-0.9kg/9.3m2 did not significantly increase feed conversion rate or 
decrease body weight. Previous research has suggested boron may have an important biological 
role in biochemical mechanisms influencing normal growth and mineral metabolism (Kurtoğlu et 
al., 2005; Çinar et al., 2015). Beginning at day-of-hatch until d21, dietary concentrations up to 
240 ppm (0.024%) boron were not detrimental to broiler performance, although boron levels 
within breast muscle and liver tissues increased proportionately with increased dietary 
concentration (Rossi et al., 1993). Moreover, boron supplementation at 20mg/kg in the basal diet 
had no impact on body weight or feed consumption in chickens; results did not suggest growth-
promotion or metabolic mineral regulation (Küçükyilmaz et al., 2017). 
Boric acid has antifungal, antiseptic and antiviral properties, and it has been used as an 
antifungal agent in the treatment of yeast infection (Hernandez-Patlan et al., 2018a). Boric acid 
has been considered as a prophylactic measure against Saprolegnia fungal infections in Atlantic 
salmon with high hatchability and survival rates following treatment (Ali et al., 2014). 
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Brittingham and Wilson, (2014) showed that growth rate of Trichomonas vaginalis, the 
protozoan causative agent of trichomoniasis in humans, was reduced with low boric acid 
concentrations (0.2%) and exhibited lethality to trichomonads at higher concentrations (≤0.4%), 
independent of environmental acidification. In an in vitro gastrointestinal model, boric acid 
appeared to decrease concentration of Salmonella Enteritidis within the intestinal compartment 
(Hernandez-Patlan et al., 2018a). However, a concentration of 0.1%, boric acid within the basal 
diet had no significant reduction in Salmonella Enteritidis during an in vivo study (Hernandez-
Patlan et al., 2018b). Dietary supplementation of boron is considered economical in that a 
100mg/kg diet was estimated to cost 0.5 US $ per one ton of prepared feed (Bozkurt and 
Kucukyilmaz, 2015). As bacterial flora are an important factor in development of histomoniasis 
development, the reduction of bacteria in vitro in addition to the antifungal properties exhibited 
by boric acid contributed to the interest in evaluating this compound for anti-histomonal 
properties (Hernandez-Patlan et al., 2018a). Considering these experiments, we hypothesized that 
boric acid might be efficacious against the trichomonad parasite H. meleagridis at the selected 
dietary concentration of 0.2%; this hypothesis is addressed in Data Chapter 2.  
VACCINATION 
Vaccinations are important for the induction of a host-immune response to protect against 
disease (Mitra et al., 2018). Previous immunological research results with histomoniasis have 
largely been unsuccessful; therefore, the likelihood of vaccine development for prevention of this 
disease has been considered unlikely (Hu and McDougald, 2004). However, turkeys recovered 
from histomoniasis and subsequently challenged to evaluate immunity have exhibited resistance 
to characteristic clinical signs and lesions even when harboring H. meleagridis within the cecae, 
suggesting the presence of immune response (Cuckler, 1970). Moreover, H. meleagridis-infected 
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turkeys rescued with dimetridazole were shown to be resistant to subsequent infection, 
suggesting an acquired protective immunity (Joyner, 1963).  
In the early 1900s, intravenous inoculation was found to eventually reproduce 
histomoniasis when injection was repeated (Tyzzer et al., 1921). Oral administration of fresh 
subcutaneous, liver, and lung lesions did not reproduce histomoniasis within turkeys (Tyzzer et 
al., 1921). Tyzzer (1921) stated that turkeys recovered from H. meleagridis infection were not 
able to be re-infected, suggesting immunity. Furthermore, histomoniasis resistance increased 
with age with only a few mature birds exhibiting clinical signs of infection (Tyzzer et al., 1921). 
However, turkeys recovered from histomoniasis only exhibited a degree of immunity that 
appeared transient rather than permanent due to the reappearance of clinically apparent disease 
several months following recovery from disease challenge (Tyzzer and Fabyan, 1922).  
Passive immunization with injection of antiserum from immune into susceptible poultry 
did not confer protection against histomoniasis upon challenge (Clarkson, 1963; Bleyen et al., 
2009). Intramuscular injection of an inactivated clonal H. meleagridis also failed to produce 
effective protection (Hess et al., 2008). These data suggest acquired immune protection is largely 
cell-mediated rather than humoral (antibody-based). Previous studies with chickens have shown 
that feed deprivation and an alkaline pH prior to oral challenge were required in order to develop 
lesions consistent with histomoniasis, suggesting that oral transfer of the parasite should not be 
overlooked (Cuckler, 1970). Liebhart et al. (2010) demonstrated a protective effect of an in vitro 
attenuated H. meleagridis administered orally to 1-day-old turkeys, further suggesting that oral 
transfer should not be disregarded. A rectally inoculated nonpathogenic strain of Histomonas 
was shown to afford some protection against challenge with pathogenic histomonads three to six 
weeks post-vaccination, but the effectiveness declined when challenge occurred via infected 
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heterakid eggs (Lund, 1959). In regards to this outcome, Lund (1959) suggested that the immune 
barrier was limited to the cecal mucosa, which could be infiltrated by the cecal worms, thus 
allowing disease development. Reduced albumin and increased γ–globulin are the primary serum 
protein changes associated with H. meleagridis infection (Clarkson, 1966). Recently, vaccination 
with attenuated histomonads reduced T and B cell subset deviation; mortality in turkeys 
suffering from histomoniasis was demonstrated to be associated with higher cellular immune 
response when compared to chickens (Mitra et al., 2017). Co-infection of H. gallinarum with H. 
meleagridis resulted in an increased mRNA expression of Th1 cytokine IFN-γ (Schwarz et al., 
2011).   
Attenuated H. meleagridis 
Following propagation for two years, an H. meleagridis culture originally pathogenic to 
chickens was found to have lost pathogenicity and induce protection against pathogenic strains 
when allowed to multiply within the chicken’s cecae (Tyzzer, 1932). Early studies by Tyzzer 
(1934) reported reduced virulence of H. meleagridis that was cultivated in vitro, although 
immunization attempts yielded conflicting success. Histomonads passaged in vitro more than 
1000 times over a period of seven years were shown to be nonpathogenic and considered to have 
lost efficacy as an immunizing strain capable of protecting against pathogenic H. meleagridis 
strains (Lund and Chute, 1967). Stable attenuation has been shown in a H. meleagridis that was 
passaged 295 times in vitro and subsequently serially passaged in vivo within turkeys and 
chickens with no reversion to virulence (Sulejmanovic et al., 2013). More recent studies within 
chickens and turkeys have shown reduction of liver and cecal lesions following intracloacal 
administration of clonal in vitro attenuated H. meleagridis utilized as a vaccine strain (Hess et 
al., 2008; Liebhart et al., 2013). Nguyen Pham et al. (2013) cloacally inoculated turkeys with a 
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low-virulence H. meleagridis strain that was obtained via serial passage in turkeys and showed 
induced protection in the face of subsequent challenge by a virulent H. meleagridis. Furthermore, 
an attenuated clonal strain of H. meleagridis developed through prolonged in vitro culture 
methods demonstrated a cross-protective capability against heterologous virulent isolates 
(Sulejmanovic et al., 2016). Pullets vaccinated at 18-week-of-age with an in vitro-attenuated, 
clonal culture exhibited reduced pathology and prevention of a severe drop in egg production as 
compared to pullets challenged without prior vaccination (Liebhart et al., 2013). Taken together, 
these data suggest that a protective immune response against histomoniasis may be induced.   
Our laboratory obtained a virulent field isolate of H. meleagridis that was able to be 
cultivated and preserved based upon previous methods (van der Heijden et al., 2005; van der 
Heijden and Landman, 2007). This virulent H. meleagridis isolate was propagated for ~80 
passages and evaluated as a live-attenuated vaccine candidate. Based upon the rapid in vitro 
growth and perceived virulence reduction within turkeys, we believed that it may be a worthy 
vaccine candidate, a topic that will be further explored in Data Chapter 3 within a disease 
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Deoxycholic acid (DCA) is a naturally occurring secondary bile acid, originating from 
intestinal bacterial metabolic conversion of cholate, a primary bile acid. DCA has been shown to 
have anti-histomonal properties in vitro, leading to our hypothesis that DCA inclusion within the 
feed may prevent histomoniasis in turkeys. Selected concentrations of DCA within a basal starter 
diet were evaluated for effects on body weight gain (BWG), lesions, and mortality of H. 
meleagridis-challenged turkeys. Treatments consisted of Negative Control, 0.25% DCA diet, 
0.5% DCA diet, 1% DCA diet, or Wild-Type (WT) Positive Control. The basal turkey starter 
diet was fed to all groups until d7, at which time DCA diets were administered to respective 
groups. Via intracloacal inoculation, 2x105 WT H. meleagridis cells/turkey were administered on 
d14, and lesions were evaluated d13 post-challenge. Pre-challenged d0-14 BWG in the 0.25% 
DCA group was higher (p≤0.05) than the 1% DCA group. There were no significant differences 
in pre-challenge d0-14 BWG between any of the other groups. No significant differences in 
mortalities from histomoniasis occurred in DCA treatment groups as compared to the WT 
Positive Control. No lesions or mortalities characteristics of histomoniasis were observed at any 
time in the Negative Control poults. Presence of classic Histomoniasis-related liver lesions was 
statistically higher in the 0.5% DCA diet as compared to the WT Positive Control. Utilizing the 
same controls and experimental timeline, an additional group was included to evaluate a 
biliogenic diet that was formulated to encourage endogenous bile acid production. The biliogenic 
diet had no statistical impact on pre-challenge d0-14 BWG, but this diet did not reduce mortality 
or lesions related to histomoniasis. Taken together, these data suggest DCA inclusion within the 
feed at these concentrations and under these experimental conditions does not prevent 
Histomoniasis. Although DCA treatment reduced H. meleagridis cells in vitro, the in vivo trial 
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resulted in no reduction of mortalities or lesion presence from histomoniasis within the DCA 
diets as compared to the WT Positive Control.  
 





 Histomoniasis, also known as blackhead, is an important disease particularly affecting 
turkeys in addition to other gallinaceous birds (van der Heijden et al., 2005; Hess et al., 2015). 
Caused by the protozoan parasite Histomonas meleagridis, mortality can approach 80-100% of 
the flock with significant economic damage incurred (Callait et al., 2002; McDougald, 2005; 
Hess and McDougald, 2013). Nitroimidazoles were previously an effective treatment for 
histomoniasis; however, regulatory action resulted in the removal of effective prophylactic and 
therapeutic compounds such as this without any alternatives introduced for disease treatment 
(Joyner, 1963; Hess and McDougald, 2013; Liebhart et al., 2013).  
Deoxycholic acid (DCA) is a naturally occurring secondary bile acid produced through 
intestinal bacterial metabolic conversion of cholate (Van Eldere et al., 1996; Ridlon et al., 2006). 
DCA has been shown to reduce severity of Eimeria maxima and Clostridium perfringens poultry 
infections when administered in a dietary concentration of 1.5 g/kg with an associated reduction 
of damaged intestinal villi (Wang et al., 2018). A study in mice demonstrated that anaerobic 
bacteria-derived DCA protected against colitis induced by Campylobacter jejuni (Sun et al., 
2018). The primary purpose of the present study was to evaluate DCA as a chemoprophylaxis 
candidate against histomoniasis. In addition, dietary composition has been shown to influence 
endogenous production of bile acids within the host (Yang et al., 2012). Therefore, a biliogenic 
diet was formulated to encourage endogenous bile acid formation in the turkey with the 






MATERIALS AND METHODS 
In vitro Assessment of Deoxycholic Acid 
 Three in vitro assays were completed to evaluate selected concentrations of high purity 
DCA sodium salt (VWR International LLC, USA). Wild-type (WT), virulent H. meleagridis 
were added at a ratio of 100µL histomonads: 50µL DCA treatment into a 96-well, sterile 
microtiter plate. Each treatment was performed in pentaplicate. Incubation occurred at 40C with 
wells capped and parafilm utilized to maintain anaerobic conditions. Following incubation, 
viable histomonads were enumerated by trypan blue 0.4% vital dye exclusion using a 
hemocytometer, and cell counts were expressed as viable histomonads/mL. 
 In Assay 1, a concentration of 2.01x106 histomonads/mL of WT H. meleagridis was 
added according to the method above. Treatments included sterile phosphate-buffered saline 
(PBS) as a negative control or selected final DCA concentrations of 0.4, 2, and 4mM. The plate 
was incubated 7-8.5 hours before viable histomonads were enumerated as described above. In 
Assay 2, a concentration of 6.88x105 histomonads/mL was used and treatments included either 
PBS control or 0.5, 1, 2, or 4mM DCA concentrations. The plate was incubated 6-8 hours before 
viable histomonads were enumerated. In Assay 3, a concentration of 6.35x105 histomonads/mL 
was added and treatments included either PBS or DCA concentrations of 0.5, 1, or 2mM. The 
plate was incubated and viable histomonads were enumerated at two time periods of 4-6 hours 
and 27-29 hours.  
Animal Source and Diet 
 A total of 140 day-of-hatch female turkey poults were obtained from a local commercial 
hatchery. Poults were neck-tagged individually and randomly allocated to floor pens at the 
University of Arkansas Poultry Health Laboratory. All animal handling procedures were in 
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compliance with the Institutional Animal Care and Use Committee (IACUC protocol #18113) of 
the University of Arkansas. A corn-soy-based starter feed that met or exceeded nutrient 
requirements for poultry (NRC, 1994) and water were provided ad libitum.  Early poult 
mortalities unrelated to histomoniasis were recorded and altered group numbers reported in the 
experiment. 
DCA diet. On d7, DCA was included in the diet at selected concentrations of either 0.25, 
0.5, or 1%. Treatments consisted of Negative Control (n=59), 0.25% DCA diet (n=20), 0.5% 
DCA diet (n=20), 1% DCA diet (n=20), and WT Positive Control (n=20).  Turkeys remained on 
treatment diets for the remainder of the experiment. 
 Biliogenic diet. Utilizing the same positive and negative controls as above, a Biliogenic 
diet treatment group (n=20) consisting of 20% whole egg powder (Heartland Supply Co., USA) 
inclusion within a basal turkey starter was evaluated. This treatment’s objective purpose was to 
physiologically upregulate natural bile acid synthesis to potentially increase endogenous DCA 
production within the turkey (Table 1). This group was subjected to the same experimental 
timeline and evaluation methods as the DCA treatment groups mentioned previously (Figure 1).     
Histomonas meleagridis Challenge 
 To initiate disease challenge, all poults other than the Negative Control received a total 
dose of 2x105 WT, virulent H. meleagridis cells/poult administered intracloacally with an animal 
gavage needle on d14. Inoculation occurred twice (at half total dosage) with 1h between 
inoculations to ensure each bird received an infectious dose.  
Lesion Scores and Body Weight Gain 
 All poults were weighed individually on d0 and d14 for calculation of pre-challenge body 
weight gain (BWG). Presence liver and cecal lesions associated with histomoniasis was recorded 
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from all mortalities following challenge. On d13, all remaining poults were necropsied for the 
presence or absence of liver and cecal lesions typical of histomoniasis. 
Statistical Analysis 
In vitro data were computed using JMP Pro 14 software. Significant differences between 
viable histomonads/mL in treatment groups were determined using ANOVA, and means were 
further separated using Tukey’s multiple comparison post hoc test with values of p≤0.05 
considered significant. Pre-challenged BWG data were also analyzed using JMP Pro 14 software, 
with significant differences between BWG in treatment groups determined using ANOVA. 
Where applicable, means were further separated using Tukey’s multiple comparison post hoc test 
with values of p≤0.05 considered significant. Mortalities and lesion presence related to 
histomoniasis were compared against the WT Positive Control using chi-square test with a 
difference of p≤0.05 considered significant.  
RESULTS 
In vitro Cell Viability Assays 
 In assay 1, mean viable histomonads/mL (Log10) for PBS, 0.4mM DCA, 2mM DCA and 
4mM DCA treatments following 7-8.5h incubation were 6.22, 6.25, 0.00, and 0.00, respectively 
(Table 2). The treatments of 2mM and 4mM DCA significantly reduced the concentration of 
viable histomonads as compared to either the PBS negative control or the 0.4mM DCA.  
In assay 2, mean viable histomonads/mL (Log10) for PBS, 0.5mM DCA, 1mM DCA, 
2mM DCA, and 4mM DCA treatments following 6-8h incubation were 6.11, 6.12, 4.71, 0.00, 
and 0.00, respectively. The treatments of 1mM, 2mM, and 4mM DCA significantly reduced the 
concentration of viable histomonads as compared to either the PBS or the 0.5mM DCA. 
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In assay 3, mean viable histomonads/mL (Log10) for PBS, 0.5mM DCA, 1mM DCA, 
and 2mM DCA following 4-6h incubation were 6.30, 6.31, 6.16, and 1.34, respectively. The 
1mM DCA treatment significantly reduced the viable histomonads as compared to PBS or 
0.5mM DCA. The 2mM DCA had lower viable histomonads as compared to all other treatments. 
Following 27-29h incubation, histomonads from assay 3 were enumerated with mean counts of 
6.48, 6.18, 4.46, and 0.00, respectively. The 0.5mM DCA treatment had lower viable histomonad 
counts as compared to the PBS. The 1mM and 2mM DCA significantly reduced viable 
histomonads as compared to either the PBS or 0.5mM DCA treatments. 
Pre-challenge BWG from d0-14 
 The selected dietary concentrations of DCA had no statistically negative impact on d0-14 
pre-challenged BWG as compared to the basal control diet. The 0.25% DCA diet had higher 
(p≤0.05) pre-challenge BWG as compared to the 1% DCA diet (Table 3). The 1% DCA diet was 
lower at pre-challenge BWG than the Negative Control but was not statistically different. No 
differences were observed in pre-challenge BWG between any of the other DCA treatments.  
Histomoniasis Infection Response and Lesions 
Differences in mortalities associated with histomoniasis were not significant between any 
of the DCA treatments as compared to the WT Positive Control (Figure 2). Presence liver and 
cecal lesions associated with histomoniasis was significantly higher in the 0.5% DCA diet as 
compared to the WT Positive Control (Figure 3). No classical lesions associated with 
histomoniasis were observed at any time in the Negative Control.  
Biliogenic Dietary Impact on Histomoniasis 
The biliogenic diet did not reduce histomoniasis.  No statistical difference was detected in 
the d0-14 pre-challenge BWG (Figure 4A). Mortalities and lesions related to histomoniasis were 
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not reduced in the biliogenic diet group as compared to the WT Positive Control (Figures 4B 
and 4C, respectively).   
  DISCUSSION 
In vitro testing of DCA effectively reduced the viability of H. meleagridis; viable 
histomonad counts decreased with increased concentration of DCA. However, dietary inclusion 
at the selected concentrations neither prevented nor mitigated the disease in H. meleagridis-
challenged turkeys. Although not statistically different, BWG during the pre-challenge phase 
decreased with increased dietary DCA as compared to the basal diet. This could indicate that the 
maximum acceptable concentration of DCA inclusion was approached, and higher DCA 
inclusion rates may not be useful if any further research is conducted. Again, although not 
statistically significant, the 0.25% and 0.5% DCA groups had higher mortalities as compared to 
the WT Positive Control. The higher lesion presence within the 0.5% DCA group as compared to 
the WT Positive Control further contributes to the conclusion from this study that DCA was not 
effective against histomoniasis under these experimental conditions. A higher inclusion rate of 
DCA would be discouraged unless further evaluation was completed to evaluate physiological 
impact. In addition, a higher concentration of DCA would likely be economically unfeasible. 
Mortalities and lesions characteristic of histomoniasis were not reduced by the biliogenic diet. 
Similarly to the DCA diets, the biliogenic diet numerically (not statistically) reduced pre-
challenge BWG as compared to the basal diet. Mortalities and lesions were not statistically 
different, although the biliogenic diet marginally increased the rates of both. If future studies 
were to be conducted, it might be beneficial to include measurement of feed intake to evaluate 
whether the poults were ingesting adequate amounts of feed compared to the basal diet.    
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According to Lefebvre et al. (2009), the “classical pathway” for bile acid synthesis 
contains the cholesterol 7α-hydroxylase (CYP7A1) and contributes to approximately 75% of bile 
acid synthesis within the liver. Cholesterol, an important precursor for bile acids, has recently 
been shown to enhance H. meleagridis growth in vitro (Gruber et al., 2018). Based on this recent 
finding by Gruber et al. (2018), the biliogenic diet formulation, which included 20% whole egg 
powder, may have increased normal cholesterol levels and inadvertently aided the parasite. Both 
lecithin-enriched and egg-enriched diets have been associated with increased total bile acid 
output (Lindsay et al., 1969; LeBlanc et al., 1998; Yang et al., 2012), but no measurements of 
bile acids were evaluated within the present study. Although DCA displayed significant 
reduction of histomonads in vitro, the ineffectiveness to prevent histomoniasis in vivo is 
consistent with the variable results of other candidates evaluated against this disease. Extracts of 
the medicinal herb Artemisia annua as well as artemisinin (a main active compound) previously 
exhibited anti-histomonal properties in vitro but failed to prevent infection within experimental 
challenged turkeys and chickens (Thøfner et al., 2012). The same H. meleagridis culture was 
utilized by Thøfner et al. (2012), but in vitro susceptibility did not translate to in vivo results. 
These findings are similar to the DCA results, further emphasizing the importance of 
incorporating in vivo evaluation of anti-histomonal chemoprophylaxis compounds rather than 
relying only upon positive in vitro data. Further confounding this already complicated disease, 
the cecal environment wherein H. meleagridis resides is constantly in a state of flux, 
demonstrating the difficulties in controlling histomoniasis. Bacterial flora contribute an 
important role in disease development; therefore, influence of chemoprophylaxis candidates on 
the gastrointestinal environment as well as the parasite should be considered (Callait et al., 2002; 
McDougald, 2005). In conclusion, DCA and the formulated biliogenic diet were evaluated for 
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the first known time against histomoniasis but none of the dietary treatments were effective in 
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Table 1. Ingredient composition of the biliogenic diet for induction of endogenous bile acids.  
 
Item1 % as-fed 
Corn  45.7 
Soybean meal 28.2 
Spray-dried egg powder2 20.0 
Dicalcium phosphate 2.75 
Limestone 1.52 
Poultry Fat 1.00 
L-lysine HCl 0.23 
Salt 0.20 
DL-methionine 0.15 
CT Tky Starter VTM 0.15 
Choline chloride (60%) 0.07 
L-threonine 0.01 
168mg of biotin was added to the premix 




Table 2.  In vitro viability assays evaluating selected concentrations of deoxycholic acid for anti-
histomonal properties.1,2 
ASSAY 1 Viable Cells/mL (Log10) 
Treatment After 7-8.5 hr. incubation 
PBS 6.22 ± 0.02
a
 
0.4 mM DCA 6.25 ± 0.03
a
 
2 mM DCA 0.00 ± 0.00
b
 
4 mM DCA 0.00 ± 0.00
b
 
ASSAY 2 Viable Cells/mL (Log10) 
Treatment After 6-8 hr. incubation 
PBS 6.11 ± 0.02
a
 
0.5 mM DCA 6.12 ± 0.05
a
 
1 mM DCA 4.71 ± 0.25
b
 
2 mM DCA 0.00 ± 0.00
b
 
4 mM DCA 0.00 ± 0.00
b
 
ASSAY 3 Viable Cells/mL (Log10) 
Treatment After 4-6hr. Incubation After 27-29 hr. incubation 
PBS 6.30 ± 0.05
a
 6.48 ± 0.01
a
 
0.5 mM DCA 6.31 ± 0.03
a
 6.18 ± 0.07
b
 
1 mM DCA 6.16 ± 0.04
b
 4.46 ± 1.25
c
 
2 mM DCA 1.34 ± 0.92
c
 0.00 ± 0.00
c
 
a-cData are expressed as the Mean ± SEM, n=5 samples. Statistical evaluation using ANOVA 
followed by Tukey’s multiple post-hoc test. Means with no common superscript differ 
significantly (p≤0.05). 
1Assay 1-3 began with concentrations of 2.01x106, 6.88x105, and 6.35x105 histomonads/mL of 
the wild-type H. meleagridis, respectively, added at a ratio of 100µL cells: 50µL treatment and 
incubated under anaerobic conditions at 40°C. 
2DCA=Deoxycholic acid 
 
Table 3. Effect of dietary inclusion of selected concentrations of deoxycholic acid on d0-14 
BWG during pre-challenge phase.  
 
Treatment d0-14 Pre-Challenge BWG (g)1 
Wild-Type Positive Control d14 270 ± 9.36ab 
0.25% DCA 289 ± 14.0a 
0.5% DCA  257 ± 13.1ab 
1% DCA 242 ± 12.4b 
Negative Control 265 ± 6.34ab 
a,bMeans ± SEM with no common superscript differ significantly (p≤0.05). 
1Statistical evaluation using ANOVA followed by Tukey’s multiple post-hoc test. 






Figure 1. In vivo trial experiment timeline.  
 
 
Figure 2. Percentage post-challenge cumulative mortality related to histomoniasis. Statistical 
difference indicated by “*” to indicate p≤0.05 as compared to the Wild-Type (WT) Positive 




Figure 3. Percentage cumulative liver and cecal lesions associated with histomoniasis beginning 
from 9d post-challenge until d13 experiment termination. Lesions were determined based on the 
presence or absence of classic histomoniasis that is characterized by target-like liver lesions and 
cecal cores. Statistical differences indicated by “*” to indicate p≤0.05 as compared to the Wild-
Type (WT) Positive Control. No lesions or mortalities associated with histomoniasis were 




Figure 4. A) Biliogenic dietary effect on d0-14 BWG during pre-challenge phase. No significant 
differences were found between BWG. B) Post-challenge cumulative mortality associated with 
histomoniasis. Statistical difference indicated by “*” to indicate p≤0.05 as compared to Wild-
Type (WT) Positive Control. C) Percentage cumulative liver and cecal lesions associated with 
histomoniasis beginning from d6 post-challenge until d13 experiment termination. No significant 
differences in lesions associated with histomoniasis were found between the biliogenic diet 
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Histomoniasis, caused by the protozoan parasite Histomonas meleagridis, is a disease to 
which turkeys are especially susceptible. Currently, no chemoprophylaxis compounds are 
available to mitigate this disease. Boric acid exhibits antifungal, antiseptic and antiviral 
properties, and it has been used in the treatment of yeast infections. Based upon these 
characteristics, an experiment was conducted to evaluate whether boric acid might be efficacious 
against H. meleagridis. Treatments consisted of Negative Control, 0.2% Boric Acid diet, and 
Wild-Type Positive (WT) Challenged Control. The 0.2% Boric Acid diet was administered to the 
respective group beginning on day-of-hatch. On d21, challenge with 2x105 H. meleagridis 
cells/turkey occurred intracloacally, and lesions were evaluated on d14 post-challenge. 
Individual body weights were recorded on d0, 21, and 35 to calculate the pre-challenge and post-
challenge body weight gain (BWG). The 0.2% Boric Acid group resulted in lower pre-challenge 
d0-21 BWG (p≤0.05) than the Negative Control. Post-challenge d21-35 BWG was not 
statistically lower (p=0.0567) than the wild-type positive control. No differences were detected 
in mortalities associated with histomoniasis between the 0.2% Boric Acid group and the WT 
Positive Control. Liver and cecal lesions were not statistically different between the 0.2% Boric 
Acid group and the WT Positive Control. Taken together, these data suggest that boric acid was 
not efficacious in the prevention or reduction of disease severity when provided at this dietary 
concentration under these experimental conditions.  
 
 





 Histomoniasis, also commonly known as blackhead, is a disease of turkeys associated 
with high mortality (Callait et al., 2002). Considered critically and economically impactful to 
both turkeys and chickens, histomoniasis is a serious concern facing the poultry industry (Duffy 
et al., 2005; Lotfi et al., 2014). Histomonas meleagridis, the etiological agent of histomoniasis, 
penetrates the cecal epithelial lining, replicates, enters the bloodstream, and parasitizes the liver 
(Clarkson, 1963; Hess and McDougald, 2013). Research on this organism waned in the 1960s 
following the introduction of nitroimidazoles, nitrofurans, and arsenical compounds for 
prophylaxis and treatment of outbreaks; compounds have since been banned due to regulatory 
action (van der Heijden et al., 2005; Hess et al., 2006). In 2015, the arsenic-based drug nitarsone 
(Histostat), the last remaining FDA-approved drug for prevention of histomoniasis, was 
withdrawn from the market due to concerns about inorganic arsenic residues in treated poultry 
(Regmi et al., 2016). Unfortunately, no alternative to the previously used drugs has been 
identified; in vitro and in vivo studies continue to yield variable results against histomoniasis 
(Thøfner et al., 2012).  
Boron is an essential element to humans, animals, and plants (Eren et al., 2012). The NRC 
(1994) has no recommended level of boron for daily intake in poultry. Within the poultry 
industry, application of boric acid, a boron compound, to the litter is used in the prevention of 
darkling beetles (Sander et al., 1991; Dufour et al., 1992). In 1992, Dufour et al. showed that 
boric acid litter treatment at a rate of 0.4-0.9kg/9.3m2 did not significantly increase feed 
conversion or decrease body weight. Previous studies have suggested the important biological 
role that boron may have on the biochemical mechanisms influencing mineral metabolism and 
normal growth (Kurtoğlu et al., 2005; Çinar et al., 2015). Dietary supplementation of boron is 
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considered economical in that a 100mg/kg diet was estimated to cost 0.5 USD per ton of 
prepared feed (Bozkurt and Kucukyilmaz, 2015). Beginning at day-of-hatch until 21d, up to 240 
ppm (0.024%) boron within the diet was not detrimental to broiler performance, although boron 
levels within breast muscle and liver tissues increased in proportion boron dietary concentration 
(Rossi et al., 1993). Boron (20mg/kg) supplementation in a basal diet had no impact on body 
weight or feed consumption in chickens; results did not suggest growth-promotion or metabolic 
mineral regulation (Küçükyilmaz et al., 2017). However, the acute oral mean lethal dose of boric 
acid in 1-day-old chicks was determined to be 2.95 ± 0.35 g/kg of body weight, resulting in the 
classification of boron as a slightly toxic chemical (Sander et al., 1991). 
Containing antifungal, antiseptic and antiviral properties, boric acid has also been used to 
treat yeast infections (Hernandez-Patlan et al., 2018a). Within an in vitro model, boric acid 
decreased concentration of Salmonella Enteritidis within the intestinal compartment (Hernandez-
Patlan et al., 2018a). However, during an in vivo study, a concentration of 0.1% boric acid within 
the basal diet had no significant reduction in Salmonella Enteritidis (Hernandez-Patlan et al., 
2018b). The growth rate of Trichomonas vaginalis, protozoan causative agent of trichomoniasis 
in humans, was reduced with low boric acid concentrations (0.2%) and exhibited lethality to 
trichomonads at higher concentrations (≤0.4%), independent of environmental acidification 
(Brittingham and Wilson, 2014). Bacterial flora are important in development of histomoniasis, 
contributing to the interest in boric acid as a potential chemoprophylactic compound against the 
disease. Considering these experiments, the antifungal properties, and the potential cost-
effectiveness, we hypothesized that boric acid might be efficacious against the trichomonad H. 




MATERIALS AND METHODS 
Animal Source and Diet 
 A total of 120 day-of-hatch female turkey poults were obtained from a local commercial 
hatchery. Poults were neck-tagged individually and randomly allocated to floor pens at the 
University of Arkansas Poultry Health Laboratory. Early poult mortalities unrelated to 
histomoniasis were recorded and the altered group numbers are reported in the experiment. All 
animal handling procedures were in compliance with the Institutional Animal Care and Use 
Committee (IACUC protocol #18113) of the University of Arkansas. A corn-soy-based starter 
feed that met or exceeded nutrient requirements of poultry (NRC, 1994) and water were provided 
ad libitum. Treatments consisted of Negative Control (n=34), 0.2% Boric Acid diet (n=27), and 
Wild-Type (WT) Positive Challenged Control (n=20). Beginning on day-of-hatch, boric acid 
(Sigma-Aldrich, St. Louis, MO) was incorporated into the basal diet at a concentration of 0.2% 
for the treatment group receiving the boric acid diet.  
Histomonas meleagridis 
On d21, all poults other than the Negative Control received a total dosage of 2x105 WT, 
virulent H. meleagridis cells/turkey administered intracloacally with an animal gavage needle. 
Inoculation occurred twice with a 1h period between each inoculation. 
Lesion Scores and Body Weight Gain 
 All poults were individually weighed on d0, 21, and 35 for calculation of pre-challenge 
and post-challenge body weight gain (BWG). Liver and cecal lesions associated with 
histomoniasis were tabulated from all mortalities. On d14 post-challenge, all remaining poults 
were necropsied to evaluate liver and cecal lesions. Classical lesions associated with 




 BWG data were analyzed using JMP Pro 14 software, with significant differences 
between treatment groups determined using a Student’s t-test with p≤0.05 considered significant. 
Differences in mortalities associated with histomoniasis were analyzed using chi square test. 
Lesion score data were analyzed using the Proc Mixed Procedure in SAS 9.4 software with 
significance between mean lesion score values considered at p≤0.05 in comparison to the WT 
Positive Control.  
RESULTS 
Pre-challenge BWG from d0-21 was significantly lower in poults fed the 0.2% Boric 
Acid diet as compared to poults fed the basal diet in the Negative Control group (Figure 1A). 
Post-challenge BWG from d21-35 in the 0.2% Boric Acid group was numerically lower than the 
WT Positive Control but not statistically different with p=0.0567 (Figure 1B). No differences 
were detected in mortalities associated with histomoniasis in the 0.2% Boric Acid group as 
compared to the WT Positive Control (Figure 1C). Moreover, neither liver nor cecal lesions were 
reduced in the 0.2% Boric Acid group as compared to the WT Positive Control following H. 
meleagridis-challenge (Figures 1D and 1E, respectively).  
DISCUSSION 
At this selected dietary concentration of boric acid, the significantly lower pre-challenged 
BWG suggests that the level of boric acid should not exceed 0.2% in the diet fed to turkeys. 
Lowered body weight gain is consistent with previous literature indicating that toxic levels of 
boric acid can induce increased feed conversion and decreased body weight (Dufour et al., 
1992). Boric acid previously resulted in high toxicity when orally administered to 1-day-old 
chicks at levels greater than 3.89 g/kg body weight (Sander et al., 1991). Efficacy of alternative 
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chemoprophylaxis compounds against related protozoa is suggested due to the close relationship 
of H. meleagridis to other amoebae and flagellates (Hu and McDougald, 2004). However, 
selective toxicity against protozoa is crucial to ensure that the chemoprophylaxis compound is 
harmful to the parasite without causing irreversible damage to the host. The early mortalities 
excluded from the data set could potentially have resulted from boric acid toxicity, but tissue 
levels and lesions other than those characteristic to histomoniasis were not considered within this 
experimental design. Overall, these data suggest that boric acid at this selected dietary 
concentration and under these experimental conditions is not effective in the mitigation of 
histomoniasis. If continued, future research should consider boric acid concentrations less than 
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Figure 1. BWG at A) Pre-challenge from d0-21 and B) post-challenge from d21-35. BWG data 
expressed as mean ± SEM and were analyzed using Student’s t-test in JMP Pro 14. C) 
Percentage of mortalities associated with histomoniasis post-challenge. No difference was 
detected when analyzed with chi square test. Cumulative lesion scores associated with 
histomoniasis beginning from d10-d14 post-challenge for D) liver and E) cecae. Lesions score of 
“0” indicative of a healthy bird with no disease whereas a score of “3” indicates classically 
severe histomoniasis.  No differences between mean lesion scores were detected with SAS Proc 
Mixed Procedure for either liver or cecal lesions. Numbers within columns indicate the total 
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No vaccines are currently available to alleviate histomoniasis, a protozoal disease 
primarily affecting turkeys. Three experiments evaluated a live-attenuated vaccine candidate 
(VC) H. meleagridis. At selected dosages and time-points, turkeys (n=~40/group) were 
vaccinated via different routes (oral vs. cloacal) and subsequently challenged with a virulent 
wild-type (WT) H. meleagridis.  
Experiment 1 included Negative Control and intracloacally-administered VC or WT on 
d14 (2x105 Histomonas cells/poult). On d29, a subset of Negative Control and all VC were WT-
challenged. On d11 post-challenge, liver and cecal lesions were tabulated.  Mortalities and 
lesions were significantly lower (p≤0.05) in the VC compared to the WT Positive Control.  
Experiment 2 included Negative Control, VC Oral (doses: 2 x103 or 2x104), VC Cloacal 
(doses: 2x103, 2x104, or 2x105), or WT Cloacal Positive Control (2x105). On day-of-hatch, 
vaccinations were administered pre-feeding via their respective routes and doses. On d21, VC 
groups were challenged intracloacally with 2x105 WT. Two challenged-only control groups were 
introduced on d21, receiving the 2x105 WT either cloacally or orally for the first time. Lesions 
were evaluated d14 post-challenge. Mortalities and lesions were higher in all groups as compared 
to the orally-administered WT. No differences in lesions were observed between the VC groups 
and the Cloacal WT Positive Control.  
Experiment 3 included Negative Control, VC Cloacal (d0 or d14), VC Oral (d0), or WT 
Cloacal Positive Control (d0, d14, or d28). A dose of 2x105 was used for both the VC and WT 
challenge. On d28, all treatments were challenged intracloacally with WT, and lesions evaluated 
d14 post-challenge. Mortalities and liver lesions were lower in the d14 VC Cloacal as compared 
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to WT Cloacal Positive Control. Cecal lesions were not different in any VC treatment group as 
compared to the WT Cloacal Positive Control.  
Although histomoniasis was not completely prevented, d14 intracloacal administration of 
the VC reduced of lesions and mortalities in experiments 1 and 3. Taken together, these data 
encourage further research with the possibility that an attenuated strain could be efficacious for 





















 Histomoniasis, also commonly known as blackhead, is an important protozoal disease 
pertaining primarily to turkeys from the etiological origin of Histomonas meleagridis (Clarkson, 
1963; Hess and McDougald, 2013). Flock mortality due to histomoniasis can approach 80-100%, 
indicating the substantial economic importance of this affliction (Callait et al., 2002; 
McDougald, 2005; Hess and McDougald, 2013). Direct contact between infected poultry or fecal 
droppings results in rapid transmission and can occur without an intermediate host or vector if 
transmission occurs before environmental degradation of the histomonad (Sentíes-Cué et al., 
2009). The primary method of transmission is considered to be through cloacal drinking that can 
quickly transfer disease through the cloaca into the bursa of Fabricius or ceca via rhythmic 
contractions (Hu et al., 2004; McDougald and Fuller, 2005). Recently, oral administration of a 
clonal in vitro cultivated H. meleagridis administered to 1-day-old turkeys followed by 5h feed 
withdrawal resulted in mortalities associated with histomoniasis; the oral route of poultry in 
contact with large amounts of contaminated excreta or litter should be further considered 
(Liebhart and Hess, 2009).  
Limited research within the past 30 years combined with the ban of therapeutic and 
prophylactic compounds has led to the absence of effective methods for controlling this disease 
(van der Heijden et al., 2005; Hess et al., 2006).  Nitarsone (Histostat), the last remaining FDA-
approved drug for treatment of histomoniasis, was withdrawn from the market in 2015 due to 
concerns over detectable levels of heavy metals retained in meat products from treated poultry 
(Regmi et al., 2016). In vitro and in vivo studies continue to yield variable results with no 
alternatives introduced to replace the recently banned effective compounds such as the 
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nitroimidazoles, nitrofurans, and arsenical compounds (Thøfner et al., 2012). Moreover, no 
vaccines are currently available to mitigate this disease.  
Results from previous immunological research has been unsuccessful, contributing to 
doubts over the possibility of vaccine development for prevention of histomoniasis (Hu and 
McDougald, 2004). However, in 1963, Joyner treated turkeys suffering from acute histomoniasis 
with dimetridazole and reported resistance to subsequent infection in the recovered turkeys, 
suggesting the development of protective immunity. Cuckler (1970) reported turkeys recovered 
from H. meleagridis-infection were resistant to subsequent challenge, even with maintained 
presence of H. meleagridis within the cecae. Early studies by Tyzzer (1934) expressed the 
reduction of virulence within long-term in vitro cultivated H. meleagridis, although 
immunization results yielded conflicting success. More recent studies with chickens and turkeys 
have indicated reduced liver and cecal lesions following intracloacal administration of clonal in 
vitro attenuated H. meleagridis lines (Hess et al., 2008; Liebhart et al., 2013). Stable attenuation 
with no reversion to virulence was demonstrated with a H. meleagridis that was passaged 295 
times in vitro and subsequently serially passaged 5 times in vivo in turkeys and chickens 
(Sulejmanovic et al., 2013). Furthermore, cross-protection against heterologous virulent isolates 
was demonstrated by vaccinating with an attenuated clonal strain of H. meleagridis developed 
through prolonged in vitro culture methods (Sulejmanovic et al., 2016). Nguyen Pham et al. 
(2013) cloacally inoculated turkeys with a low-virulent H. meleagridis strain that was obtained 
via serial passage in turkeys and showed induced protection following subsequent challenge with 
a virulent H. meleagridis. Moreover, Liebhart et al. (2010) demonstrated a protective effect of an 
in vitro attenuated H. meleagridis administered orally to 1-day-old turkeys. Development of a 
vaccine against histomoniasis is encouraged by these immunological research advances. 
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Therefore, the objective of this study was to evaluate an H. meleagridis strain that was passaged 
in vitro for immune protection in an experimental histomoniasis challenge model and to further 
elucidate the possible routes and age for administration.  
MATERIALS AND METHODS 
Animal Source 
Poults were tagged individually and randomly allocated to floor pens at the University of 
Arkansas Poultry Health Laboratory on day-of-hatch. All animal handling procedures were in 
compliance with the Institutional Animal Care and Use Committee (IACUC protocol #18113 and 
#19032) of the University of Arkansas. A corn-soy based starter feed that met or exceeded 
nutrient requirements of poultry (NRC, 1994) and water were provided ad libitum. Early poult 
mortalities unrelated to histomoniasis were recorded and the altered group numbers are reported 
in the experiments. 
Histomonas meleagridis Isolate and Culture 
A virulent wild-type (WT) H. meleagridis was obtained and cultivated based upon 
previously published methods (van der Heijden et al., 2005; van der Heijden and Landman, 
2007). The WT was passaged approximately 80 times and chosen for evaluation as a live-
attenuated vaccine candidate (VC). Modified Dwyer’s Media (MDM) was used for H. 
meleagridis cultivation (Gibco, Life Technologies Corporation, USA; Lonza Walkersville Inc.; 
USA), supplemented with 10% heat-inactivated horse serum (Gibco) and 1.6mg/mL white rice 
flour. Histomonads were incubated anaerobically at 40°C for 48-72h before 1mL was sub-
cultured into 12.5mL of fresh, supplemented MDM.  Growth was confirmed by observation with 
an inverted microscope or enumeration on a hemocytometer. For long-term preservation of H. 
meleagridis, 10% dimethylsulfoxide (OmniSolv, MilliporeSigma, USA) was added as a 
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cryoprotectant. The suspension was then distributed into cryogenic vials (VWR, USA) and 
allowed to freeze at approximately -1°C/min under controlled conditions until reaching -80°C, at 
which time vials were transferred to long-term storage in a liquid nitrogen tank. Approximately 6 
days before needed for challenge or vaccination, the desired H. meleagridis aliquot was retrieved 
from the liquid nitrogen and cultured into fresh supplemented media. Passages occurred every 
48-72h. Following incubation, viable histomonads/mL were enumerated on a hemocytomer. 
Within each experiment, MDM was utilized as the diluent to prepare the proper dosage 
concentration. 
Lesion Scoring System 
The lesion score system was developed and initiated during “phase 2” of experiment 1 
and continued throughout the remainder of the study. Classic lesions associated with 
histomoniasis were evaluated on a scale of “0-3”, with “3” being the most severe (Figure 1). The 
individuals determining the lesion scores were blinded to the treatment groups. All mortalities 
were evaluated for liver and cecal lesions. According to this scale, a liver score of: “0” presents 
with no detectable H. meleagridis-related lesions, “1” indicates detectible lesions that are not 
clinically relevant (not significant ongoing pathology), “2” signifies intermediate lesions 
suggesting significant pathology but not imminent mortality, while “3” denotes confluent or 
nearly confluent lesions deemed likely to be fatal. The cecae were observed and palpated from 
the serosal surface (the mucosa was not evaluated).  According to the scale, a cecal score of: “0” 
indicates no detectable H. meleagridis-related lesions observed from serosal inspection and 
palpation, “1” denotes thickening (not clinically significant) of the cecae, “2” indicates clinically 
meaningful cecal wall thickening without cecal cores, “3” specifies classic typhlitis with 




Phase 1 (d14-29). A total of 120 day-of-hatch female turkey poults were obtained from a 
local commercial hatchery. Groups included a non-challenged Negative Control (n=59), the 
Vaccine Candidate (VC) (n=39), and the Wild-Type (WT) Challenged Positive Control (n=20). 
On d14, the VC group was inoculated with an in vitro attenuated (passage ~80) H. meleagridis at 
a total dose of 2x105 histomonads/poult, and the WT Positive Control group received a total dose 
of 2x105 virulent WT histomonads/poult (Figure 2). Inoculations were administered 
intracloacally with an animal gavage needle and occurred twice with approximately 1h between 
each inoculation. On d27 (13d post-challenge), the WT Positive Control group from “phase 1” 
was euthanized to evaluate characteristic disease lesions and used for comparison against the 
VC-induced lesions. On d28 (d14 post-vaccination), a subset of n=5 poults was sampled from 
both the Negative Control and VC groups to evaluate for lesions associated with histomoniasis.  
Phase 2 (d29-40). On d29 (d15 post-vaccination), all poults except the Negative Control 
were challenged with the WT using the previously mentioned procedure. A newly introduced 
d29 WT Cloacal Positive Control was created from a subset of the Negative Control group to 
serve as concurrent reference against the VC group. All mortalities were evaluated for 
characteristic liver and cecal lesions pertaining to histomoniasis. On d40 (d11 post-challenge), all 
remaining poults were euthanized by CO2 inhalation and lesions were tabulated according to the 
method described above.     
Experiment 2 
A total of 280 day-of-hatch female turkey poults were obtained from a local commercial 
hatchery and allocated to groups. Treatments included non-challenged Negative Control (n=34), 
VC Oral 2x103 (n=36), VC Oral 2x104 (n=38), VC Cloacal 2x103 (n=36), VC Cloacal 2x104 
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(n=37), VC Cloacal 2x105 (n=30), and WT Cloacal Positive Control 2x105 histomonads/poult 
(n=36). In addition, a total of 30 day-of-hatch poults were humanely euthanized for pH 
measurement of the combined proventriculus-ventriculus region using pH indicator strips 
(Sigma-Aldrich, St. Louis, MO, USA). 
Phase 1 (d0-21). On day-of-hatch, poults were vaccinated prior to feeding with selected 
doses of either 2x103, 2x104, or 2x105 histomonads/poult with in vitro attenuated (passage ~80) 
H. meleagridis administered either orally or intracloacally (Figure 4). The WT Cloacal Positive 
Control received 2x105 histomonads/poult of WT, virulent H. meleagridis via intracloacal 
administration according to the method described in experiment 1. On d15, a sample from each 
group was evaluated for lesions to compare the VC to the WT group, leaving a remaining subset 
of n=20 from each VC treatment group for the following challenge “phase 2.”  
Phase 2 (d21-35). A WT Oral Positive Control (n=14) and WT Cloacal Positive Control 
(n=20) were introduced on d21 and were created from reallocation of the Negative Control 
poults. On d21, all poults received intracloacal challenge with WT H. meleagridis at 2x105 total 
histomonads/poult in a pair of inoculations, with the exception of the WT Oral Positive Control 
which received this dose orally in a single administration. On d35 (d14 post-challenge), all 
remaining poults were euthanized by CO2 inhalation and lesion scores were tabulated according 
to the method described above.  
Experiment 3 
A total of 480 day-of-hatch female turkey poults were obtained from a local commercial 
hatchery and allocated to groups. Treatments included Negative Control (n=217), d0 VC Oral 
(n=53), d0 VC Cloacal (n=52), d0 WT Oral Positive Control d0 (n=60), and d0 WT Cloacal 
Positive Control d0 (n=60). In addition, a total of 60 day-of-hatch poults were humanely 
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euthanized and the pH of the combined proventriculus-ventriculus region was measured in each 
poult using pH indicator strips (Sigma-Aldrich, St. Louis, MO, USA).  
Phase 1 (d0-14). On day-of-hatch and prior to feeding, poults received selected doses of 
2x105 histomonads/poult of either the WT challenge or the in vitro attenuated (passage ~80) VC 
H. meleagridis administered either orally or cloacally according to the method described above 
(Figure 7). On d14, all poults from the WT Oral Positive Control and WT Cloacal Positive 
Control were evaluated for liver and cecal lesions. A total of n=10 poults/group were likewise 
evaluated from the Negative Control, d0 VC Oral, and d0 VC Cloacal groups to compare to the 
WT lesion presence. 
Phase 2 (d14-28). Treatments included Negative Control (n=108), d0 VC Oral (n=43), d0 
VC Cloacal (n=42), d14 VC Cloacal (n=56), and d14 WT Cloacal Positive Control (n=43). On 
d14, the newly introduced WT Cloacal Positive Control and VC Cloacal group received 2x105 
histomonads/poult of WT or VC H. meleagridis strain administered intracloacally, respectively. 
On d28, all poults from the d14 WT Cloacal Positive Control were evaluated for liver and cecal 
lesions. A total of n=10 poults/group were likewise evaluated from the Negative Control and d14 
VC Cloacal groups. A total of n=5 poults/group were evaluated from the d0 VC Oral and d0 VC 
Cloacal groups.  
Phase 3 (d28-42). Treatments included Negative Control (n=53), d0 VC Oral (n=38), d0 
VC Cloacal (n=37), d14 VC Cloacal (n=45), and d28 WT Cloacal Positive Control (n=45). On 
d28, all poults except for the Negative Control, received 2x105 cells/poult of the WT H. 
meleagridis challenge via intracloacal administration. On d42, all remaining poults were 





Differences in mortalities associated with histomoniasis were analyzed using the chi 
square test with p≤0.05 considered significant. Fisher’s Exact test (2018 GraphPad Software, 
LLC) was performed to further examine the mortality relationship between the Cloacal VC 
2x105 group and the Cloacal WT Positive Control when difference was not apparent via the chi 
square test. Lesion score data were analyzed using the Proc Mixed Procedure in SAS 9.4 
software with significance between mean lesion score values denoted at p-values of ≤0.05, 
≤0.005, or ≤0.0005 in comparison to the WT Positive Control.    
RESULTS 
Experiment 1 
Phase 1 (d14-28). No mortalities associated with histomoniasis occurred in the Negative 
Control or VC, whereas the WT Positive Control reached 30% mortality before euthanasia on 
13d post-challenge (d27) (Figure 3A). No indications of histomoniasis were observed in the 
Negative Controls at any time. Cumulative lesions from mortalities and scheduled termination 
date of the WT Positive Control revealed 75% liver and 80% cecal lesions characteristic of 
histomoniasis. On d28 (d14 post-vaccination), among the n=5 VC subset examined, one VC 
poult exhibited normal liver and cecae under gross examination, whereas two poults had 
presented with normal livers but relatively normal cecae with the exception of small, button-like 
lesions. One poult had target-like liver lesions with the cecae feeling hard, thickened, and 
exhibiting larger bumps and scalloping. The fifth VC poult exhibited paling edges to the liver, 
narrow and thin margins, and was possibly beginning to develop liver lesions. In addition, the 
cecae were large, with the presence of thickened walls and scalloping.  
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Phase 2 (d29-40). Mortalities relating to histomoniasis within the Negative Control, VC, 
and WT Positive Control were 0.00, 2.94, and 22.2%, respectively (Figure 3B). The Negative 
Control and VC mortalities were different (p≤0.05) as compared to the WT Positive Control. The 
VC displayed lower liver (p≤0.0005) and cecal (p≤0.005) lesions than the WT Positive Control 
(Figures 3C and 3D). No lesions or mortalities associated with histomoniasis were observed in 
the Negative Control.   
Experiment 2 
Phase 1 (d0-21). A mean pH of 4.4 was determined from the proventriculus-ventriculus 
region from the day-of-hatch poults. Mortalities related to histomoniasis in the Negative Control, 
VC Oral 2x103, VC Oral 2x104, VC Cloacal 2x103, VC Cloacal 2x104, VC Cloacal 2x105, and 
WT Cloacal Positive Control were 0.00, 2.78, 2.63, 0.00, 5.41, 3.33, and 22.2%, respectively 
(Figure 5A). Mortalities in the Negative Control and all VC groups were lower (p≤0.05) than the 
WT Cloacal Positive Control. Liver and cecal lesions were lower (p≤0.0005) in all VC Oral and 
VC Cloacal groups as compared to the WT Cloacal Positive Control (Figures 5B and 5C).  
Phase 2 (d21-35). Mortalities related to histomoniasis in the WT Oral Positive Control, 
VC Oral 2x103, VC Oral 2x104, VC Cloacal 2x103, VC Cloacal 2x104, VC Cloacal 2x105, and 
WT Cloacal Positive Control were 0.00, 50.0, 50.0, 60.0, 55.0, 35.0, and 55.0%, respectively 
(Figure 6A). The WT Oral Positive Control had lower (p≤0.05) mortalities as compared to the 
WT Cloacal Positive Control. No differences in mortalities were found between any of the VC 
treatments as compared to the WT Cloacal Positive Control when evaluated with a chi square 
test. To further elucidate any possible difference between the VC Cloacal 2x105 group as 
compared to the WT Cloacal Positive Control, a Fisher’s Exact test was computed, resulting in 
p=0.3406. The WT Oral Positive Control resulted in lower (p≤0.0005) liver and cecal lesions as 
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compared to the WT Cloacal Positive Control (Figures 6B and 6C). The WT Oral Positive 
Control received only lesion scores of “0”, indicating no detectable lesions associated with 
histomoniasis. No differences in liver or cecal lesions were found between any of the VC groups 
as compared to the WT Cloacal Positive Control. The p-values for the VC Cloacal 2x105 as 
compared to the WT Cloacal Positive Control for liver and cecal lesions were p=0.1610 and 
p=0.6793, respectively.  
Experiment 3 
Phase 1 (d0-14). A mean pH of 5.0 was determined from the proventriculus-ventriculus 
region from the day-of-hatch poults. No mortalities associated with histomoniasis occurred in the 
Negative Control, VC Oral, or VC Cloacal groups (Figure 8A). The d0 WT Oral Positive 
Control and d0 WT Cloacal Positive Control resulted in 16.7 and 15% mortalities by d14 post-
challenge, respectively. The d0 WT Oral Positive Control was not different in liver or cecal 
lesions (p=0.0908 and p=0.2360, respectively) as compared to the d0 WT Cloacal Positive 
Control (Figures 8B and 8C). The d0 VC Oral and d0 VC Cloacal were lower in liver (p≤0.005) 
lesions and cecal (p≤0.0005) lesions as compared to the d0 WT Cloacal Positive Control. 
Negative Control was lower (p≤0.0005) in liver and cecal lesions as compared to the d0 WT 
Cloacal Positive Control.  
Phase 2 (d14-28). No mortalities associated with histomoniasis occurred in the Negative 
Control, d0 VC Oral, d0 VC Cloacal, or d14 VC Cloacal groups by 28-days-of-age. The d14 
introduced WT Cloacal Positive Control reached 48.8% mortality by d14 post-challenge (Figure 
9A). The d0 VC Oral, d0 VC Cloacal, d14 VC Cloacal, and Negative Control were lower 
(p≤0.05) in liver and cecal lesions as compared to the d14 WT Cloacal Positive Control (Figures 
9B and 9C).  
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Phase 3 (d28-42). No mortalities or lesions associated with histomoniasis occurred in the 
Negative Control. Mortalities in the d0 VC Oral, d0 VC Cloacal, d14 VC Cloacal, and d28 WT 
Cloacal Positive Control reached 44.7, 32.4, 22.2, and 42.2%, respectively (Figure 10A). The 
d14 VC Cloacal group resulted in lower (p≤0.05) mortalities than the d28 WT Cloacal Positive 
Control. Liver and cecal lesions were different (p≤0.0005) between the Negative Control and 
d28 WT Cloacal Positive Control. The d14 VC Cloacal group exhibited lower (p≤0.0005) 
cumulative liver lesions than the d28 WT Cloacal Positive Control (Figure 10B). Although not 
statistically significant (p=0.0899), the d14 VC Cloacal group somewhat reduced cecal lesions as 
compared to the d28 WT Cloacal Positive Control (Figure 10C). No differences were detected 
in liver or cecal lesions between any of the other VC groups as compared to the d28 WT Cloacal 
Positive Control. 
DISCUSSION 
The VC lessened the severity of histomoniasis when administered at a total dosage of 
2x105 histomonads/turkey on d14 in experiment 1. The decreased mortalities following WT 
challenge and the lack of vaccine-related mortalities suggested that this passage strain of H. 
meleagridis might be attenuated enough to initiate immune response within the turkey without 
resulting in lethality due to the VC. Although disease was not completely prevented, the lowered 
lesions and mortalities as compared to the WT Cloacal Positive Control suggest that some 
protection was offered via the VC. Within all of the experiments, the Negative Controls never 
exhibited mortalities or lesions associated with histomoniasis, further confirming that disease can 
be prevented by management and absence of exposure.  
In experiment 2, low vaccine-related mortalities associated with histomoniasis occurred 
in the oral (doses of 2x103 and 2x104) and cloacal (doses of 2x103 and 2x105) VC which could 
71 
 
potentially be explained since the H. meleagridis VC is not a clonal population. Variation may 
be occurring each time the cells are propagated, with greater or fewer virulent cells present at 
various concentrations depending upon the passage. During phase 1 of experiment 2, lesion 
presence was lower in the subsets of VC turkeys regardless of dose or route when compared to 
the WT Cloacal Positive Control, suggesting that the VC H. meleagridis was still capable of 
invading the tissues without causing characteristic rampant lesions. Although prolonged in vitro 
passaging of H. meleagridis has been reported to decrease vaccination efficacy against 
pathogenic strains, stable attenuation occurred in other studies without reversion to virulence 
(Lund and Chute, 1967; Sulejmanovic et al., 2013). 
 Oral transfer of H. meleagridis should not be overlooked as previous studies with 
chickens have demonstrated that feed deprivation and an alkaline pH prior to oral challenge were 
required in order to develop lesions characteristic with histomoniasis (Cuckler, 1970). 
Interestingly, WT oral challenge on d21 resulted in no mortalities or lesions associated with 
histomoniasis, consistent with the prevailing thoughts that H. meleagridis cannot survive the low 
pH within the proventriculus and ventriculus typically present following feed consumption. 
Conversely, in experiment 3, turkeys that were WT challenged orally on d0 were equally 
susceptible to H. meleagridis infection with no differences noted in mortalities or lesions as 
compared to the WT Cloacal Positive Control. Following feed ingestion, the average pH in the 
proventriculus/ventriculus has been reported as 3.5 in broiler chickens with variability between 
1.9 and 4.5 (Svihus, 2011). The susceptibility of the poults on day-of-hatch pre-feeding could 
likely be explained by the higher pH (measured as 4.4 and 5.0 in experiments 2 and 3, 
respectively) within the proventriculus/ventriculus region, indicating a more basic environment 
for which the protozoa could potentially survive until parasitizing the cecae. If repeated in future 
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studies, pH should be measured in a subset of turkeys post-feeding to compare to pre-feeding 
measurements. Unexpectedly, the subset of the d0 VC Oral (dose 2x105) in experiment 3 
exhibited some mild to severe lesions characteristic with histomoniasis when evaluated on d28 
post-vaccine, indicating the ability of the VC H. meleagridis to invade tissue although no 
mortalities related to the disease occurred during this timeframe.  
Some turkeys within the WT Cloacal Positive Control group in each experiment 
exhibited lesion scores of “0”, indicating no abnormality or pathology of histomoniasis. The 
absence of lesions within a subset of the WT Cloacal Positive Control could potentially be 
explained in that some turkeys may be less susceptible to challenge, cecal retrograde of the 
parasite inoculum could vary between turkeys, or some turkeys may excrete the inoculum before 
cloacal uptake occurs. Moreover, the absence of clonal culture could contribute to prevalence of 
certain cell populations with greater or lower degrees of virulence. Although passages of the WT 
H. meleagridis are minimized to prevent in vitro attenuation in culture, a chance of virulence or 
population changes are present with each propagation. To reduce this concern, both the WT and 
VC should be single-cell cloned and evaluated to ensure the same genetic population is being 
evaluated in subsequent experiments. 
Liebhart et al. (2010) demonstrated protectiveness of an in vitro attenuated H. 
meleagridis administered to 1-day-old turkeys. However, under the conditions of these 
experiments, the cloacal route appears to be the more efficacious route as compared to the oral 
route for administration, especially at an older age. Administration of the VC H. meleagridis 
intracloacally on d14 resulted in lower mortalities and lesions in both experiments 1 and 3, 
suggesting that this might be an efficacious alternative for the prevention of histomoniasis. 
Intracloacal inoculation with attenuated H. meleagridis has shown induced protection as well as 
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cross-protective capability against virulent isolates (Nguyen Pham et al., 2013; Sulejmanovic et 
al., 2016). Further research should be conducted to elucidate the most efficacious route and 
dosage of the VC H. meleagridis as well as the proper age for administration. It should be noted 
that other passage isolates of H. meleagridis have been evaluated by other research groups and 
shown to induce protection against subsequent challenge, as outlined above. Additionally, if our 
selected VC is efficacious at alleviating histomoniasis and is successfully single-cell cloned, we 
will need to address a major limiting factor to larger scale production of the live-attenuated H. 
meleagridis strain, specifically more efficient methods to feasibly propagate cells to meet 
commercial production needs. The current cell culture methods seem unfeasible for mass 
production, as the cells grow at varied rates and the media is relatively costly. Moreover, for 
introduction to the industry, the intracloacal route would not be the most practical technique for 
large-scale application. The d0 administration would be preferable for industry application for 
incorporation within the hatchery. Presumably, oral route at day-of-hatch seems the most 
efficient, if possible. However, if the cloacal route proves to be the only effective administration 
to induce a robust immune response, then potentially an alternative method could be developed 
for cloacal application during the beak trimming, toenail removal, or sex determination 
procedure at the hatchery. Certainly, a main consideration is the identification of an effective 
prophylaxis for this life-threatening disease of poultry. The current lack of any approved 
prophylactic measures against histomoniasis suggests that any contribution to the mitigation of 
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Figure 1. Histomoniasis lesion scoring system developed at the University of Arkansas Poultry 
Health Laboratory. Classic lesions associated with histomoniasis for liver and cecae were 
evaluated on a scale of “0”-“3.” A score of “0” indicates no detectible lesions; “1” indicates 
lesions not clinically relevant; “2” signifies intermediate lesions suggesting significant pathology 













Figure 3. Experiment 1 cumulative percentage mortalities associated with histomoniasis at A) 
Phase 1 (d14-29) and B) Phase 2 (d29-40). Lesion scores on 11d post-challenge for C) liver and 
D) cecae. Statistical difference detected by the SAS Proc Mixed Procedure between mean lesion 
scores as compared to the Wild-Type (WT) Positive Control group is indicated by “*” for 
p≤0.05, “**” for p≤0.005, and “***” for p≤0.0005. Numbers within columns indicate the total 










Figure 5. Experiment 2 response during Phase 1 (d0-21) for A) cumulative percentage of 
mortalities associated with histomoniasis, lesion scores of B) liver and C) cecae at 15d post-
administration of Vaccine Candidate (VC) or Wild-Type (WT) Histomonas meleagridis. 
Statistical difference detected by the SAS Proc Mixed Procedure between mean lesion scores as 
compared to the Wild-Type (WT) Positive Control group is indicated by “*” for p≤0.05, “**” for 
p≤0.005, and “***” for p≤0.0005. Numbers within columns indicate the total poults per 




Figure 6.  Experiment 2 response during Phase 2 (d21-35) for A) cumulative percentage of 
mortalities associated with histomoniasis, lesion scores of B) liver and C) cecae beginning from 
d9-14 post-WT challenge. Statistical difference detected by the SAS Proc Mixed Procedure 
between mean lesion scores as compared to the Wild-Type (WT) Positive Control group is 
indicated by “*” for p≤0.05, “**” for p≤0.005, and “***” for p≤0.0005. Numbers within 










Figure 8. Experiment 3 response during Phase 1 (d0-14) for A) cumulative percentage of 
mortalities associated with histomoniasis, lesions scores of B) liver and C) cecae on d14 post-
administration of Vaccine Candidate (VC) or Wild-Type (WT) Histomonas meleagridis. 
Statistical difference detected by the SAS Proc Mixed Procedure between mean lesion scores as 
compared to the Wild-Type (WT) Positive Control group is indicated by “*” for p≤0.05, “**” for 
p≤0.005, and “***” for p≤0.0005. Numbers within columns indicate the total poults per 





Figure 9. Experiment 3 response during Phase 2 (d14-28) for A) cumulative percentage of 
mortalities associated with histomoniasis, lesion scores of B) liver and C) cecae. Statistical 
difference detected by the SAS Proc Mixed Procedure between mean lesion scores as compared 
to the Wild-Type (WT) Positive Control group is indicated by “*” for p≤0.05, “**” for p≤0.005, 
and “***” for p≤0.0005. Numbers within columns indicate the total poults per evaluated lesion 





Figure 10. Experiment 3 response during Phase 3 (d28-42) for A) cumulative percentage of 
mortalities associated with histomoniasis, lesion scores of B) liver and C) cecae. Statistical 
difference detected by the SAS Proc Mixed Procedure between mean lesion scores as compared 
to the Wild-Type (WT) Positive Control group is indicated by “*” for p≤0.05, “**” for p≤0.005, 
and “***” for p≤0.0005. Numbers within columns indicate the total poults per evaluated lesion 




None of the dietary treatments of deoxycholic acid (DCA), biliogenic formulation, or 
boric acid reduced disease within H. meleagridis-challenged turkeys. Although DCA exhibited 
anti-histomonal properties in vitro, efficacy was not transferred in vivo under the experimental 
conditions of this study. These results further confirm the complicated nature of this disease as 
well as the importance of in vivo evaluation rather than reliance only upon in vitro methods.  
Under the conditions of experiment 1 within the vaccination study, the Vaccine 
Candidate (VC) Histomonas meleagridis resulted in lowered disease-related mortalities and 
lesions as compared to the Wild-Type Cloacal Positive Control. Although histomoniasis was not 
completely prevented, d14 intracloacal administration of the VC lowered lesions and mortalities 
in experiments 1 and 3. Taken together, these data suggest the potential efficacy of the VC to 
protect from histomoniasis. Further research should be conducted to elucidate the most effective 
dosage, route, and age for administration of this VC. 
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